Search

Your search keyword '"Nair SA"' showing total 81 results

Search Constraints

Start Over You searched for: Author "Nair SA" Remove constraint Author: "Nair SA" Search Limiters Full Text Remove constraint Search Limiters: Full Text
81 results on '"Nair SA"'

Search Results

1. Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

2. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA

4. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic: a modelling analysis

5. The High Penetrability of Nanoparticles into Bacterial Membranes: A Key of a Potential Application

6. A Festa das Tribos: perspectivas folkcomunicativas em um cenário de resistência

7. Optical and antimicrobial properties of silver nanoparticles synthesized via green route using honey

8. Performance investigation of a rotary heat exchanger installed with four ducts using computational fluid dynamics

9. Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model

10. Differential gene expression analysis of in vitro duck hepatitis B virus infected primary duck hepatocyte cultures

11. Molecular characterization of Chikungunya virus isolates from clinical samples and adult Aedes albopictus mosquitoes emerged from larvae from Kerala, South India

12. Saber do espaço e colonização regional: constituição territorial e expedições geográficas no sudoeste do Paraná

13. MicroRNA-532-3p Modulates Colorectal Cancer Cell Proliferation and Invasion via Suppression of FOXM1.

14. Mitochondria-targeted biotin-conjugated BODIPYs for cancer imaging and therapy.

15. Biocompatible Aza-BODIPY-Biotin Conjugates for Photodynamic Therapy of Cancer.

16. Individuals' Vulnerability Based Active Surveillance for TB: Experiences from India.

17. Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness.

18. STIL Endows Oncogenic and Stem-Like Attributes to Colorectal Cancer Plausibly by Shh and Wnt Signaling.

19. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.

20. Upfront Xpert MTB/RIF for diagnosis of pediatric TB-Does it work? Experience from India.

21. Modelling the potential impact of adherence technologies on tuberculosis in India.

22. The potential deployment of a pan-tuberculosis drug regimen in India: A modelling analysis.

23. Picolyl Porphyrin Nanostructures as a Functional Drug Entrant for Photodynamic Therapy in Human Breast Cancers.

24. Tuberculosis treatment in the private healthcare sector in India: an analysis of recent trends and volumes using drug sales data.

25. Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer.

26. Modelling the impact of effective private provider engagement on tuberculosis control in urban India.

27. Higher risk of developing active TB among adult diabetics exposed to TB during childhood: A study from Kerala, India.

28. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.

29. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation.

30. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.

31. "Before Xpert I only had my expertise": A qualitative study on the utilization and effects of Xpert technology among pediatricians in 4 Indian cities.

32. Catalysing progressive uptake of newer diagnostics by health care providers through outreach and education in four major cities of India.

33. Accelerating access to quality TB care for pediatric TB cases through better diagnostic strategy in four major cities of India.

34. Operational research within a Global Fund supported tuberculosis project in India: why, how and its contribution towards change in policy and practice.

35. Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: An economic analysis.

36. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.

37. Bottom-up or top-down: unit cost estimation of tuberculosis diagnostic tests in India.

38. Integration and decentralisation of TB-HIV services increases HIV testing of TB cases in Rajasthan, India.

39. Bis(3,5-diiodo-2,4,6-trihydroxyphenyl)squaraine photodynamic therapy disrupts redox homeostasis and induce mitochondria-mediated apoptosis in human breast cancer cells.

40. What a difference a day makes: same-day vs. 2-day sputum smear microscopy for diagnosing tuberculosis.

42. Key diffusion mechanisms involved in regulating bidirectional water permeation across E. coli outer membrane lectin.

43. Factors Associated with Tuberculosis and Rifampicin-Resistant Tuberculosis amongst Symptomatic Patients in India: A Retrospective Analysis.

44. EK3D: an E. coli K antigen 3-dimensional structure database.

45. Piloting Upfront Xpert MTB/RIF Testing on Various Specimens under Programmatic Conditions for Diagnosis of TB & DR-TB in Paediatric Population.

46. The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.

47. Adverse drug reactions in tuberculosis patients: consequences for TB control.

48. Has introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India?

49. Evaluation of TB Case Finding through Systematic Contact Investigation, Chhattisgarh, India.

50. Dual drug delivery of 5-fluorouracil (5-FU) and methotrexate (MTX) through random copolymeric nanomicelles of PLGA and polyethylenimine demonstrating enhanced cell uptake and cytotoxicity.

Catalog

Books, media, physical & digital resources